Patients treated with Opdivo plus Yervoy with two cycles of chemotherapy showed sustained improvements in overall survival and progression-free survival and increased duration of response vs.

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the first presentation of results from the Phase 3 CheckMate -9LA trial, which demonstrated a statistically ...

This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with ...

Bristol-Myers Squibb Company announced that CheckMate -9LA, a pivotal phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy ...

Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable. The ...

Combination nivolumab (Opdivo) and ipilimumab (Yervoy) with chemotherapy offered a durable survival benefit versus chemotherapy alone in advanced non-small cell lung cancer (NSCLC) with brain ...

The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet ...

A first-line immune checkpoint inhibitor combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival in patients with advanced non-small cell lung cancer (NSCLC) when added to a ...

Bristol-Myers Squibb Company BMY announced that the pivotal, phase III study — CheckMate-9LA — evaluating a combination regimen of its PD-1 inhibitor, Opdivo, in first-line advanced non-small cell ...

Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include ...